An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer

Greimel, Elfriede; Bottomley, Andrew; Cull, Ann; Waldenström, Ann-Charlotte; Arrarás, Juan Ignacio; Chauvenet, L.; Holzner, Bernhard; Kuljanić, Karin; Lebrec, Jérémie; D’Haese, Sven

doi:10.1016/s0959-8049(03)00307-1

Cited by 189 publications

(129 citation statements)

References 8 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…For function scales, high scores indicate better function (improved QOL); for symptom scales, higher scores indicate greater symptoms (poorer QOL). The QLQ‐C30 and the QLQ‐OV28 have undergone extensive psychometric validation and multiple translations and are acceptable to patients 20. A between‐groups difference of 10 to 15 points in the QLQ‐C30 global health score was previously defined as having moderate clinical significance 21…”

Section: Methodsmentioning

confidence: 99%

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

Stark

Cook

Brown

et al. 2017

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum‐sensitive relapsed ovarian cancer when it was used with chemotherapy and was continued as maintenance therapy. This study describes health‐related quality of life (QOL) during the first year of treatment.METHODSFour hundred fifty‐six women were randomly allocated to receive standard chemotherapy only, chemotherapy with concurrent cediranib, or chemotherapy with cediranib administered concurrently and continued as maintenance. Patients completed QOL questionnaires until disease progression every 3 weeks during chemotherapy and then every 6 weeks to 1 year. Patients alive with disease progression completed a QOL form 1 year after randomization. The primary QOL endpoint was the global score from the Quality of Life Questionnaire Core 30 (of the European Organization for Research and Treatment of Cancer) at 1 year, with the standard chemotherapy group compared with the concurrent‐maintenance cediranib group.RESULTSThe rate of questionnaire compliance was 90% at the baseline and 76% at 1 year and was similar across the 3 groups. The mean global QOL score at 1 year was 62.6 points for the standard chemotherapy group and 68.7 points for the concurrent‐maintenance group (+4.5; 95% confidence interval, –2.0 to 11.0; P = .18). Sensitivity analyses suggested that this finding was robust to the effect of missing data, and the improvement became statistically significant after adjustments for self‐reported diarrhea.CONCLUSIONSThe 6th study by the International Collaboration in Ovarian Neoplasm (ICON6) showed a significant improvement in progression‐free survival with cediranib as concurrent and maintenance therapy. No QOL detriment with cediranib was found 1 year after treatment was commenced. The maintenance of QOL along with prolonged cancer control suggests that cediranib has a valuable role in the treatment of relapsed ovarian cancer. Cancer 2017;123:2752‐61. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Methodsmentioning

confidence: 99%

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

Stark

Cook

Brown

et al. 2017

Cancer

View full text Add to dashboard Cite

show abstract

“…Higher scores represent a greater degree of symptoms except for the sexual functioning of the QlQ-OV28 and sexual activity and enjoyment in the QlQ-CX24) [27,28].…”

Section: The Rehabilitation Programmementioning

confidence: 99%

Goal setting in cancer rehabilitation and relation to quality of life among women with gynaecological cancer

et al. 2015

View full text Add to dashboard Cite

AbstrActbackground. Rehabilitation should be integrated in the routine cancer care of women treated for gynaecological cancers. Goal setting is expected to facilitate the process through patient involvement and motivation. Our knowledge about goal setting in cancer rehabilitation is, however, sparse. Objectives. This study aimed to: 1) analyse rehabilitation goals defined during hospital-based rehabilitation in patients with gynaecological cancer, with regard to number, category, changes over time, and differences between cancer diagnosis, and 2) analyse the association between health-related quality of life and goals defined for rehabilitation. Material and methods. Consecutively, all patients treated surgically for endometrial, ovarian, and cervical cancer were invited for hospital-based rehabilitation at Odense University Hospital, Denmark, including two sessions at the hospital one and three months following surgery and two phone calls for follow-up. Questionnaires from the EORTC were used to prepare patients and facilitate individual goal setting with definitions of up to three goals. All goals were grouped into six categories. results. A total of 151 (63%) patients accepted the invitation including 50 endometrial, 65 ovarian, and 36 cervical cancers patients. All patients defined goals at the first session, 76.4% defined three goals, 21.9% two, and 1.6% had one goal. Physical goals decreased over time but were the most frequent at both sessions (98% and 89%). At both sessions, the social and emotional categories were the second and third most frequent among patients with endometrial and ovarian cancer. Sexual issues were dominant among the cervical cancer patients. Regression analysis showed significant association between quality of life scores and goal setting within the social and emotional domains. conclusion. Goal setting seemed feasible in all problem areas. The EORTC questionnaires were helpful during the process although expectations of the sub-scores being predictive of which areas to address were not convincing.

show abstract

“…These symptoms may include abdominal swelling, fullness, pain or cramps, indigestion, change of bowel habit, etc. Abdominal pain and bowel habit change can also arise from treatment (Cain et al, 1998;Base-Enquist et al, 2001;Cull et al, 2001;Greimel et al, 2003aGreimel et al, , 2003b.…”

Section: Abdominal (Gastrointestinal) Symptomsmentioning

confidence: 99%

“…In addition to the cross-cultural validation of the EORTC, Chie et al (2010) reported the translation and validation of the EORTC QLQ-OV28 in Taiwan and found a relatively low importance of body image, menopausal, and sexuality problems because of low emphasis on attractiveness and avoidance of sexual activity after having cancer. Greimel et al (2003b) reported the result of cross-cultural validation of the EORTC QLQ-OV28 used with the EORTC QLQ-C30. The internal consistency (Cronbach's alpha) coefficients of all subscales except body image (0.58) were above 0.70 (ranging from 0.77 to 0.90).…”

Section: Reliability and Validity Of The Fact System In Patients Withmentioning

confidence: 99%

Quality Of Life Of The Patients With Ovarian Cancer

Yan

2011

IJO

View full text Add to dashboard Cite

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer

Cited by 189 publications

References 8 publications

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial

Goal setting in cancer rehabilitation and relation to quality of life among women with gynaecological cancer

Quality Of Life Of The Patients With Ovarian Cancer

Contact Info

Product

Resources

About